Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection.

Eleven pediatric patients, aged 1 to 10 years and with symptomatic human immunodeficiency virus infection, were treated with 6 or 10 mg of oral ribavirin per kg of body weight daily for 60 days. Safety and pharmacokinetic parameters were monitored; five children had comprehensive pharmacokinetic eva...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

I whakaputaina i:	Antimicrob Agents Chemother
Ngā kaituhi matua:	Connor, E, Morrison, S, Lane, J, Oleske, J, Sonke, R L, Connor, J
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	American Society for Microbiology (ASM) 1993
Ngā marau:	Research Article
Urunga tuihono:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC187703/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8460922/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.37.3.532
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!